PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
The results of the EMBRACA trial were presented today at the 2017 San Antonio Breast Cancer...
Ribociclib extends progression-free survival in pre-menopausal patients with metastatic hormone receptor-positive breast cancer
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (...
MD Anderson applauds court-ordered corrective statements from tobacco industry to educate public about harms of tobacco use
As an institution dedicated to ending cancer, The University of Texas MD Anderson Cancer Center is committed to promoting cancer prevention...
Quality of care for older Texas patients with colon cancer on the rise, still room for improvement
Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly among older Texas patients with colon cancer since 2001, while adherence to chemotherapy guidelines has remained largely unchanged. The study, published today in Cancer, identifies factors influencing adherence rates, including socioeconomic status and access to skilled physicians.
The researchers...
Chronic stress hormones may promote resistance to EGFR inhibitors in lung cancer patients
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used...
MD Anderson’s Moon Shots Program celebrates five-year anniversary
The University of Texas MD Anderson Cancer Center celebrates the five-year anniversary of its Moon Shots Program™, a collaborative effort...
Bacteria in the gut modulates response to immunotherapy in melanoma
Bacteria that live in the human digestive tract can influence how cancer responds to immunotherapy, opening a new avenue for research to improve...
Sarah Ann Roder receives MD Anderson’s highest nursing honor
Sarah Ann Roder, a clinical nurse in the Gynecologic Oncology Outpatient Center at The University of Texas MD Anderson Cancer Center,...
Baytown community launches Be Well™ Baytown initiative led by MD Anderson and ExxonMobil
In an effort to improve public health and lower the risk of cancer, Baytown community organizations are partnering with The University of...
MD Anderson Hosts A Conversation With a Living Legend® with philanthropist Rich Kinder
Houston philanthropist Rich Kinder, executive chairman of Kinder Morgan Inc., will join Houston-based NBC News correspondent Janet Shamlian...
Drug yields high response rates for lung cancer patients with harsh mutation
A targeted therapy resurrected by the Moon Shots Program™ at The University of Texas MD Anderson Cancer Center has produced unprecedented...
Cattlemen for Cancer Research to host annual auction Oct. 21
Cattlemen for Cancer Research (CCR) will hold its 19th annual auction Saturday, Oct. 21 at the Hills Prairie Livestock Auction Company, 1177...
Registration open for Nov. 11 Boot Walk to End Cancer®
The University of Texas MD Anderson Cancer Center has opened registration for the second annual Boot Walk to End Cancer®, Saturday, Nov...
Researchers compose guidelines for handling CAR T cell side effects
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge...
MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on...
MD Anderson Cancer Center to provide free skin cancer screenings at 2017 TOUR Championship
As the official cancer center of the PGA TOUR, The University of Texas MD Anderson Cancer Center will provide complimentary skin cancer screenings...
Rogers Award honors William Atkinson for Excellence in Administration
William Atkinson is the 2017 recipient of the Julie and Ben Rogers Award for Excellence in Administration at The University of Texas MD Anderson...
MD Anderson receives $7.5 million in CPRIT funding for research and facility support
The University of Texas MD Anderson Cancer Center this week was awarded $7.5 million from the Cancer Prevention and Research Institute of...
Former MD Anderson President Dr. Charles A. LeMaistre Passes Away at 92
Charles Aubrey “Mickey” LeMaistre, M.D., past president of The University of Texas MD Anderson Cancer Center and a pioneering crusader against...
Checkpoint inhibitors fire up different types of T cells to attack tumors
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell...
Study shows biomarkers can predict which ER-positive breast cancer patients respond best to first-line therapy
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard...
Combination therapy targets genetic mutation found in many cancers
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused...
HPV vaccine may reduce oral infections by as much as 88 percent
ABSTRACT: 6003
Researchers have found that the human papillomavirus (HPV) vaccine may reduce the rate of oral HPV infections in young...
Andrew Sabin Family Fellows to receive $100,000 in research funding
The University of Texas MD Anderson Cancer Center named eight innovative researchers to the second annual class of Andrew Sabin Family Fellows...
American Dental Association and MD Anderson Announce Collaboration
The American Dental Association (ADA) and The University of Texas MD Anderson Cancer Center today announced a joint effort to improve patient...
UT System hosts annual Eliminate Tobacco Use Summit
The University of Texas System convened its 2nd Annual Eliminate Tobacco Use Summit April 17-18 in Austin to enhance tobacco control...
Local restaurants and businesses bring prom to MD Anderson
The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party...
Pathologic complete response to neoadjuvant therapy in certain breast cancer patients predicts low risk for local metastases
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and...
MD Anderson and Lion Biotechnologies announce strategic alliance to conduct clinical trials of TILs in multiple solid tumors
The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies...
Protein identified as potential druggable target for pancreatic cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC),...
MD Anderson celebrates the mission of Kick Butts Day
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts...
Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard...
MD Anderson study ties protein ‘reader’ ENL to common leukemia
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid...
MD Anderson receives $19.5 million in CPRIT funding for recruitment and prevention
The University of Texas MD Anderson Cancer Center this week was awarded $19.5 million from the Cancer Prevention and Research Institute of...
MD Anderson designated first Project ECHO superhub for oncology
Recognizing a critical need to address disparities in cancer care, The University of Texas MD Anderson Cancer Center has been designated as...
MD Anderson welcomes FDA proposed rule to limit carcinogen levels in smokeless tobacco
The University of Texas MD Anderson Cancer Center fully supports the proposed rule released today by the U.S. Food and Drug Administration...
‘Collateral’ lethality may offer new therapeutic approach for cancers of the pancreas, stomach and colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known...
MD Anderson and nation’s cancer centers jointly endorse updated HPV vaccine recommendations
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united...
MD Anderson and EMD Serono enter three-year strategic collaboration to accelerate development of investigational oncology/immuno-oncology compounds
The University of Texas MD Anderson Cancer Center and EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and...